Skip to content
naulon
Not checkedNot checked for notices yet.

The expression and antigenicity of a truncated spike-nucleocapsid fusion protein of severe acute respiratory syndrome-associated coronavirus

Qiu Yan, Huang Shengyong, Fan Baoxing and 7 more

BMC Microbiology · 2008

doi:10.1186/1471-2180-8-207 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

<p>Abstract</p> <p>Background</p> <p>In the absence of effective drugs, controlling SARS relies on the rapid identification of cases and appropriate management of the close contacts, or effective vaccines for SARS. Therefore, developing specific and sensitive laboratory tests for SARS as well as effective vaccines are necessary for national authorities.</p> <p>Results</p> <p>Genes encoding truncated nucleocapsid (N) and spike (S) proteins of <it>SARSCoV </it>were cloned into the expression vector <it>pQE30 </it>and fusionally expressed in <it>Escherichia coli </it>M15. The fusion protein was analyzed for reactivity with SARS patients' sera and with anti-sera against the two human coronaviruses <it>HCoV </it>229E and <it>HCoV </it>OC43 by ELISA, IFA and immunoblot assays. Furthermore, to evaluate the antigen-specific humoral antibody and T-cell responses in mice, the fusion protein was injected into 6-week-old BALB/c mice and a neutralization test as well as a T-cell analysis was performed. To evaluate the antiviral efficacy of immunization, BALB/c mice were challenged intranasally with <it>SARSCoV </it>at day 33 post injection and viral loads were determined by fluorescent quantitative RT-PCR. Serological results showed that the diagnostic sensitivity and specificity of the truncated S-N fusion protein derived the SARS virus were > 99% (457/460) and 100.00% (650/650), respectively. Furthermore there was no cross-reactivity with other two human coronaviruses. High titers of antibodies to <it>SRASCoV </it>appeared in the immunized mice and the neutralization test showed that antibodies to the fusion protein could inhibit <it>SARSCoV</it>. The T cell proliferation showed that the fusion protein could induce an antigen-specific T-cell response. Fluorescent quantitative RT-PCR showed that BALB/c mice challenged intranasally with <it>SARSCoV </it>at day 33 post injection were completely protected from virus replication.</p> <p>Conclusion</p> <p>The truncated S-N fusion protein is a suitable immunodiagnostic antigen and vaccine candidate.</p>

Abstract licence: CC BY-NC-ND

Cited by papers we hold1

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.